<DOC>
	<DOC>NCT00004786</DOC>
	<brief_summary>OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.</brief_summary>
	<brief_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution and digital cutaneous ulcers. Patients receive oral iloprost or placebo twice daily for 6 weeks. Thrombolytic drugs, oral anticoagulants, and heparin are prohibited on study. Concurrent therapy with angiotensin-converting enzyme inhibitors for Raynaud's is prohibited; calcium channel blockers for severe digital ischemia are allowed as needed. Patients are followed at 2 and 6 weeks.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma, Systemic</mesh_term>
	<mesh_term>Scleroderma, Diffuse</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Raynaud's phenomenon secondary to systemic sclerosis (SS) SS meets American College of Rheumatology diagnostic criteria At least 6 Raynaud's attacks per week Prior/Concurrent Therapy No prior participation in oral iloprost study At least 4 weeks since participation in other investigational drug studies At least 2 months since prostanoid therapy At least 12 months since sympathectomy of upper limb Ongoing therapy for systemic sclerosis may continue on study Raynaud's therapy discontinued at entry Patient Characteristics Hematopoietic: No platelet disorder Hepatic: No bleeding diathesis Renal: Creatinine clearance (estimated) at least 30 mL/min Cardiovascular: No unstable angina pectoris None of the following within 3 months: Stroke Transient ischemic attack Myocardial infarction Other: No active cancer or other uncontrolled disease No current history of alcohol or drug abuse No mental disorder precluding compliance No pregnant or nursing women Negative pregnancy test required of fertile women Adequate contraception required of fertile women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>Raynaud's syndrome</keyword>
	<keyword>arthritis &amp; connective tissue diseases</keyword>
	<keyword>cardiovascular and respiratory diseases</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic sclerosis</keyword>
</DOC>